Sign in
Taking people in United StatesNo phase

Brain protection filter during transcatheter aortic valve replacement for aortic stenosis

Tests a filter that guards the brain during aortic valve replacement through the leg artery.

Key facts

Who runs it
EnCompass Technologies, Inc.
Where
Charlottesville, Cleveland, Columbus, Detroit, Indianappolis, Kansas City, Naples, and New York, United StatesSee the 8 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Status
Recruiting
People taking part
500 people, planned
Started
9 Sept 2025
Expected to end
Jan 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • F2 Filter and Delivery System
  • Transcatheter Aortic Valve Replacement (TAVR)
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with aortic stenosis (a narrowed heart valve) who are scheduled for TAVR through the groin artery. It tests whether the F2 filter, which catches debris on its way to the brain, works better than no filter.

Age
21 to 90 years
Sex
All sexes
Disease stage
Aortic stenosis. People must meet the usual criteria for commercially available TAVR through the groin artery and already be scheduled for it. Urgent or emergency TAVR is not allowed.
Earlier treatment
No earlier artificial heart valve in any position. No heart procedure (such as pacemaker placement, BAV, PCI) within 30 days before TAVR, and none planned within 30 days after. No diagnostic heart catheterization within 10 days before TAVR.

Main reasons for not taking part

  • Heart attack within 3 months, or stroke or TIA (mini-stroke) within 6 months
  • Weak heart pumping (LVEF < 30%), cardiogenic shock, or systolic blood pressure < 90 mm Hg
  • Kidney problems (creatinine > 2.5 mg/dL (221 µmol/L) or GFR < 30) or on dialysis, or severe liver failure (Child-Pugh class C)
  • Bleeding disorders, recent upper stomach or gut bleeding, or not able to take blood thinners
  • Cannot have an MRI scan, for example because of a pacemaker, metal implants or claustrophobia; pregnant or breastfeeding

The registry criteria, word for word

Show all 42 criteriaShow less

Who can take part

  • Age ≥ 21 and ≤ 90 years
  • Patient meets the established criteria and indications for commercially available TAVR (e.g., balloon expandable SAPIEN valve platform, self-expanding CoreValve platform, or Navitor TAVI System) via transfemoral access and is scheduled to undergo TAVR per their treating physician
  • Patient is willing and able to comply with protocol-specified follow-up evaluations
  • Patient is able and willing to provide written informed consent

Who cannot take part

  • Any interventional cardiovascular procedure performed within 30 days prior to TAVR procedure (e.g., pacemaker placement, BAV, PCI) or planned within 30 days post-TAVR procedure
  • Current or planned participation in any investigational device/biopharma study during the duration of this study protocol
  • Diagnostic cardiac catheterization within 10 days prior to TAVR procedure (Note: unplanned diagnostic catheterization is allowed during TAVR procedure, but must be performed prior to insertion of the investigational device into the vasculature)
  • Concomitant non-valvular intervention, vascular intervention, or leaflet modification is planned at time of TAVR procedure. (Note: balloon aortic valvuloplasty during TAVR procedure is permitted)
  • Evidence of an acute myocardial infarction within 3 months prior to TAVR procedure
  • Prior prosthetic heart valve in any position
  • Active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the 3 months prior to TAVR procedure
  • Contraindications to MRI (participants with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure)
  • Presence of cardiovascular implant in aorta and/or peripheral access vessels (e.g., thoracic endovascular aortic repair [TEVAR]/endovascular abdominal aortic aneurysm repair [EVAR], iliac/superficial femoral artery [SFA] stent)
  • Access vessels with excessive tortuosity or complex anatomy that would likely necessitate a surgical cutdown approach (e.g., distance from skin to vessel is extensive)
  • Active infection or endocarditis
  • Severe allergy or known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, nickel-titanium and/or contrast sensitivity that cannot be adequately pre-medicated
  • Presence or history of bleeding diathesis or coagulopathy
  • Hepatic failure (Child-Pugh class C)
  • Any other condition that in the opinion of the investigator precludes study participation or poses a significant hazard to the patient; Neurological Exclusion Criteria:
  • Active major psychiatric disease, known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation
  • Severe visual, auditory, or learning impairment
  • Neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities; Note: use of general anesthesia during TAVR may affect neurocognitive function shortly after the procedure. While not an exclusion criterion, it is recommended that general anesthesia not be used, if possible; Magnetic Resonance Imaging Exclusion Criteria:
  • Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath, vascular access or filter deployment
  • Contraindicated for anti-platelet and/or anticoagulant therapy
  • Renal insufficiency (creatinine > 2.5 mg/dL or GFR < 30) and/or renal replacement therapy at the time of screening
  • Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 30%
  • General Exclusion Criteria:
  • Participants are not eligible for the study if any of the following criteria are present:
  • General Exclusion Criteria:
  • Requires an urgent or emergent TAVR procedure
  • Known intracardiac thrombus
  • Refuses blood transfusion
  • Presenting with cardiogenic shock or requiring vasopressor or inotropic support, or with severe hypotension (systolic blood pressure < 90 mm Hg) at the time of randomization
  • Females who are pregnant or nursing or plan to become pregnant during their participation in the study. Female participants of child-bearing potential must have a negative pregnancy test at screening
  • Modified Rankin Scale (mRS) ≥ 2 at screening
  • Cerebrovascular event including TIA within 6 months of the procedure
  • Body Mass Index (BMI) precluding imaging in scanner
  • High risk of complete AV block after TAVR, with the need of permanent pacemaker (e.g., patients with pre-existing bifascicular block or complete right bundle branch block plus any degree of AV block)
  • Claustrophobia precluding MRI scanning; Anatomical and CT Exclusion Criteria:
  • Aortic arch, which is heavily calcified, severely atheromatous, or severely tortuous
  • Ascending aortic diameter less than 18 mm or greater than 38 mm measured 6 to 8 cm from the annulus
  • Transverse aortic arch diameter less than 18 mm or greater than 27 mm when measured immediately proximal to the ostium of the left subclavian artery

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 90 years old?

Where in United States

Also in 1 other country, 2 sites

  • University of Virginia Medical CenterCharlottesville, United StatesContact: Linda Bailes BrycelandNot yet recruiting
  • Cleveland Clinic FoundationCleveland, United StatesContact: Emily TylickiTaking people
  • Ohio Health Research Institute (aka Riverside Methodist Hospital)Columbus, United StatesContact: Maureen McCormackNot yet recruiting
  • Henry Ford HospitalDetroit, United StatesContact: Stephen KrafchakTaking people
  • St. Vincent HospitalIndianappolis, United StatesContact: Kelly VerelTaking people
  • St. Lukes Hospital of Kansas CityKansas City, United StatesContact: Caroline KempterTaking people
  • NCH Baker Hospital-Naples Heart InstituteNaples, United StatesContact: Kathy ByrdNot yet recruiting
  • Cumc/NyphNew York, United StatesContact: Kate DaltonTaking people

About the trial

What the trial wants to find out

The objective of this pivotal study is to compare the safety and effectiveness of the F2 CPC (Treatment group) to a Control group (no embolic protection) in participants undergoing transfemoral (TF) TAVR with commercially available devices.

The 2 groups in the trial

  • F2 Filter and Delivery SystemTreatment being tested

    The F2 Cerebral Embolic Protection System will be used during your Transcatheter Aortic Valve Replacement procedure.

    Treatment: F2 Filter and Delivery System and Transcatheter Aortic Valve Replacement (TAVR)

  • No embolic protection deviceExisting treatment, for comparison

    No embolic protection device will be used during your Transcatheter Aortic Valve Replacement procedure.

    Treatment: Transcatheter Aortic Valve Replacement (TAVR)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Randomized, Multicenter, Single-blind Trial to Assess the Safety and Effectiveness of the Encompass F2 Cerebral Protection Catheter Vs. Unprotected Transfemoral Transcatheter Aortic Valve Replacement
Plain-language title
Brain protection filter during transcatheter aortic valve replacement for aortic stenosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06689839, who can take part
Record updated
6 November 2026